Loxo Oncology Inc (NASDAQ:LOXO) VP Jennifer Burstein sold 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, September 13th. The shares were sold at an average price of $166.96, for a total transaction of $417,400.00. Following the completion of the sale, the vice president now directly owns 1,250 shares in the company, valued at $208,700. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Jennifer Burstein also recently made the following trade(s):

  • On Tuesday, August 14th, Jennifer Burstein sold 2,500 shares of Loxo Oncology stock. The shares were sold at an average price of $159.24, for a total transaction of $398,100.00.
  • On Monday, July 9th, Jennifer Burstein sold 1,500 shares of Loxo Oncology stock. The shares were sold at an average price of $187.25, for a total transaction of $280,875.00.
  • On Tuesday, June 19th, Jennifer Burstein sold 1,700 shares of Loxo Oncology stock. The shares were sold at an average price of $176.99, for a total transaction of $300,883.00.

Shares of LOXO stock traded down $1.38 during trading hours on Friday, hitting $164.00. 289,685 shares of the company’s stock were exchanged, compared to its average volume of 224,740. The company has a market capitalization of $5.02 billion, a PE ratio of -30.89 and a beta of 2.25. Loxo Oncology Inc has a 12-month low of $71.45 and a 12-month high of $208.95.

Loxo Oncology (NASDAQ:LOXO) last posted its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.15. The business had revenue of $42.60 million for the quarter, compared to analysts’ expectations of $32.36 million. During the same period last year, the business posted ($0.94) earnings per share. equities analysts forecast that Loxo Oncology Inc will post -0.47 EPS for the current fiscal year.

A number of equities research analysts recently weighed in on the stock. JMP Securities raised their target price on shares of Loxo Oncology from $182.00 to $221.00 and gave the company a “buy” rating in a research note on Monday, June 4th. BidaskClub raised shares of Loxo Oncology from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 7th. Citigroup raised their target price on shares of Loxo Oncology to $235.00 and gave the company a “buy” rating in a research note on Monday, June 4th. Stifel Nicolaus raised their target price on shares of Loxo Oncology from $190.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, June 4th. Finally, William Blair reaffirmed a “buy” rating on shares of Loxo Oncology in a research note on Monday, June 4th. Two investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Loxo Oncology presently has an average rating of “Buy” and a consensus price target of $188.40.

Several hedge funds have recently bought and sold shares of LOXO. Point72 Asset Management L.P. purchased a new position in shares of Loxo Oncology during the second quarter worth approximately $55,115,000. BlackRock Inc. raised its stake in shares of Loxo Oncology by 15.5% during the second quarter. BlackRock Inc. now owns 2,095,164 shares of the biopharmaceutical company’s stock worth $363,468,000 after acquiring an additional 280,475 shares in the last quarter. Aquilo Capital Management LLC purchased a new position in shares of Loxo Oncology during the second quarter worth approximately $21,999,000. Lord Abbett & CO. LLC raised its stake in shares of Loxo Oncology by 20.8% during the first quarter. Lord Abbett & CO. LLC now owns 666,771 shares of the biopharmaceutical company’s stock worth $76,926,000 after acquiring an additional 114,963 shares in the last quarter. Finally, Emerald Advisers Inc. PA purchased a new position in shares of Loxo Oncology during the second quarter worth approximately $16,174,000. 97.46% of the stock is currently owned by hedge funds and other institutional investors.

Loxo Oncology Company Profile

Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

Featured Article: Stock Symbol

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.